Biofrontera (BFRI) 2nd Annual Lytham Partners Healthcare Investor Summit summary

Key presentations and company updates

• Biofrontera highlighted strong revenue growth, reaching $37.3 million in 2024, with significant margin expansion after acquiring full ownership of Ameluz and manufacturing responsibilities, leading to gross margins rising from 50% to 80-85% by 2025.

• Ameluz, a photodynamic therapy for actinic keratosis, is expanding its label to cover more indications, including basal cell carcinoma (FDA approval expected by September 2026) and moderate to severe acne (pending trial data).

• Biofrontera is targeting a $500 million market opportunity by converting cryotherapy users to PDT, leveraging strong reimbursement and field therapy advantages.

• LSL Pharma Group reported rapid growth, projecting over CAD 60 million in 2026 revenue, driven by three segments: contract manufacturing (CMO), eye care, and newly acquired OTC private label business.

• LSL’s CMO division expects CAD 45 million in 2026 revenue, with recent acquisitions boosting scale and synergies, while the eye care segment is set for expansion with new in-licensed products and FDA approval for U.S. market entry.

Strategic initiatives and growth plans

• Biofrontera is optimizing its commercial team, refining go-to-market strategies, and expects low double-digit revenue growth through 2026, supported by new indications and improved sales force productivity.

• LSL Pharma is integrating recent acquisitions (Juno OTC and Duvar) and aims to reach CAD 100 million in revenue within two years through organic growth and further M&A.

• LSL’s eye care business is positioned to contribute 50% of top line and 70% of EBITDA in the medium term, with capacity expansion and first-to-market generics for the U.S. and international markets.

• Both companies emphasize strong intellectual property, quality, and expanding product portfolios to drive future growth.

Financial outlook and capital structure

• Biofrontera expects to reach breakeven in 2026, supported by improved gross margins and financing secured after the 2025 asset deal.

• LSL Pharma’s gross margins vary by segment: ophthalmic (50-75%), CMO (25-35%), and OTC (25%), with a focus on shifting mix toward higher-margin eye care.

• LSL completed refinancing in 2025 and is focused on maintaining a strong balance sheet to support growth and shareholder value.